Výsledky vyhledávání - "Selene E. Di Carlo"

Supplementary Table 1 from Negative Regulation of β4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression

Autor: Rita Falcioni, Marcella Mottolese, Giovanni Blandino, Silvia Soddu, Ada Sacchi, Maria Felice Brizzi, Gabriella D'Orazi, Chiara Lazzari, Paolo Avetrani, Valentina Folgiero, Selene E. Di Carlo, Giulia Bon

Supplementary Table 1 from Negative Regulation of β4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a01d9be1b5adb3d3ba05326d0ef172f8
https://doi.org/10.1158/0008-5472.22377752

Zobrazit plný text záznamu

PDGFRα-induced stromal maturation is required to restrain postnatal intestinal epithelial stemness and promote defense mechanisms

Autor: Jean-Marie Jacob, Selene E. Di Carlo, Igor Stzepourginski, Anthony Lepelletier, Papa Diogop Ndiaye, Hugo Varet, Rachel Legendre, Etienne Kornobis, Adam Benabid, Giulia Nigro, Lucie Peduto

Publikováno v: Cell Stem Cell
Cell Stem Cell, 2022, 29 (5), pp.856-868.e5. ⟨10.1016/j.stem.2022.04.005⟩

International audience; After birth, the intestine undergoes major changes to shift from an immature proliferative state to a functional intestinal barrier. By combining inducible lineage tracing and transcriptomics in mouse models, we identify a pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf9cfe7ae06f1fedca672a6af451132f
https://pubmed.ncbi.nlm.nih.gov/35523143

Zobrazit plný text záznamu

Akademický článek

Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.

Autor: Valentina Folgiero, Paolo Avetrani, Giulia Bon, Selene E Di Carlo, Alessandra Fabi, Cecilia Nisticò, Patrizia Vici, Elisa Melucci, Simonetta Buglioni, Letizia Perracchio, Isabella Sperduti, Laura Rosanò, Ada Sacchi, Marcella Mottolese, Rita Falcioni

Publikováno v: PLoS ONE, Vol 3, Iss 2, p e1592 (2008)

BackgroundTamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. Its benefits in adjuvant treatment are well documented in controlled and randomized clinical studies, which have demonstrated an increase in

Externí odkaz: https://doaj.org/article/66d59f94593e4c78821476da0f2174ef

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání